Somatostatin Analogs (CPB 0693, reviewed 2026-07-15)
Aetna's somatostatin analog policy (CPB 0693) applies to commercial medical plans and requires precertification for octreotide acetate (Sandostatin, Sandostatin LAR Depot), lanreotide (Somatuline or generic), pasireotide diaspartate (Signifor) and pasireotide pamoate (Signifor LAR) in applicable plan designs. Aetna considers these drugs medically necessary for the listed indications, including acromegaly, Cushing's disease, carcinoid syndrome, neuroendocrine tumors and Zollinger-Ellison syndrome, and experimental, investigational or unproven for all other indications. Octreotide, pasireotide and lanreotide are not covered for constitutional (idiopathic) tall stature.